skip to content

research · 543245 · healthcare

gland.

the case for, the case against.

positivemedium convictionwritten 16 nov 2026, 17:14 ist · valid until 23 nov 2026

positive: the sourced evidence makes a specific case that the business is improving or under-appreciated. medium conviction: a reasonable case, resting on fewer or partly second-hand sources.

the case, in short
  • In Q2 FY2027, revenue was INR 18,336 million, up 23% year-on-year, and profit after tax grew 58% year-on-year to INR 2,908 million.

the main risk
  • A US FDA inspection of the Dundigal facility in October ended with four procedural observations.

in plain words

In Q2 FY2027, sales from its business were INR 18,336 million, up 23% compared with the same period a year earlier, and net profit, after all costs and tax, grew 58% to INR 2,908 million. Reported operating profit for the quarter was INR 4,804 million, so operating profit was 26% of revenue, compared with approximately 21% in the same quarter of the previous year. The US was the company's largest market, with revenues up 42% compared with the same period a year earlier to INR 11,795 million. A US FDA inspection of the Dundigal facility in October ended with four procedural observations.

why it may work

  • In Q2 FY2027, revenue was INR 18,336 million, up 23% year-on-year, and profit after tax grew 58% year-on-year to INR 2,908 million.

  • During the quarter, CDMO revenues grew 31% year-on-year to INR 8,227 million, contributing approximately 45% of total revenues.

  • Reported EBITDA for the quarter was INR 4,804 million, an EBITDA margin of 26%, compared with approximately 21% in the same quarter of the previous year.

  • The US was the company's largest market, with revenues up 42% year-on-year to INR 11,795 million, and the company launched four products in the US market during the quarter.

what could go wrong

  • A US FDA inspection of the Dundigal facility in October ended with four procedural observations.

  • Rest-of-world revenues were INR 2,044 million in the quarter and were affected by supply and tender issues in some markets, especially the delayed announcement of NUPCO tender results in Saudi Arabia.

price and valuation facts

  • Closed at its 52-week closing high.
  • Last close ₹3,395 sits 100% of the way from the 52-week closing low (₹1,597.25) to the high (₹3,395).
  • Its largest fall from a peak in the last year was 15.8% (maximum drawdown).
  • P/E of 36.91x (standalone) is 44% below the median of its BSE 500 industry peers (sector peers when the industry has fewer than four).
  • Annualised volatility over 3 months is 29.1%, lower than 61% of the BSE 500 scrips Dalal tracks.
  • Median daily BSE traded value: ₹11.18 crore over 60 days.

dalal's own computed data (from exchange prices and bse fundamentals), not from the documents above. as of 16 nov 2026.

what is coming up

  • Additional bag manufacturing capacity installed during the year is awaiting a US FDA inspection, after which the company could sell products made on this line.

  • The company has initiated a greenfield project at Vizag SEZ, acquired land for it, and said it will seek Board approval for additional capex for this expansion in the coming quarter.

what would change the view

the view rests on these. if they stop being true, so does the view.

  • According to a whalesbook report, the company is keeping its guidance of 15% constant currency revenue growth for FY27.

the numbers

computed by dalal when the note was written.

price

last close
₹3,395.00
1-day change
1.81%
52-week high (closing basis)
₹3,395.00
52-week low (closing basis)
₹1,597.25
52-week high (BSE, adjusted)
₹3,428.00
52-week low (BSE, adjusted)
₹1,575.00

as of 16 nov 2026

returns

1-week return
2.84%
1-month return
11.56%
3-month return
16.73%
6-month return
57.23%
12-month return
85.43%
3-month return relative to SENSEX
10.51%
6-month return relative to SENSEX
44.23%
12-month return relative to SENSEX
90.98%

as of 16 nov 2026

risk

annualised volatility (3 months)
29.10%
maximum drawdown (1 year)
−15.82%
distance from 52-week closing high
0.00%
5-day vs 60-day BSE volume
0.16×

as of 16 nov 2026

valuation

P/E (standalone)
36.91×
P/E (consolidated)
45.33×
P/B
6.11×
EPS (standalone)
₹91.97
EPS (consolidated)
₹74.90
P/E relative to industry median
0.56×

as of 16 nov 2026

quality

return on equity
16.54%
operating margin
44.16%
net margin
30.31%

as of 16 nov 2026

size & liquidity

median daily BSE traded value (60 days)
₹11 cr
market capitalisation
₹56,021 cr

as of 16 nov 2026

latest results (standalone)

revenue, standalone (Sep-26)
₹1,402 cr
net profit, standalone (Sep-26)
₹425 cr
EPS, standalone (Sep-26)
₹25.75
operating margin, standalone (Sep-26)
44.16%
revenue, standalone (Jun-26)
₹1,287 cr
net profit, standalone (Jun-26)
₹364 cr
EPS, standalone (Jun-26)
₹22.11
operating margin, standalone (Jun-26)
41.37%
revenue change Jun-26 → Sep-26
8.96%
net profit change Jun-26 → Sep-26
16.60%

as of 14 nov 2026

dalal scores

daily score
60/100
monthly score
97/100
six-month score
100/100
long-term score
94/100

as of 16 nov 2026

not available: next results board meeting; days since last results filing.

· · . fundamentals from bse are standalone figures. scores are percentile ranks across the bse 500 (90 = better than 90% of them on that horizon’s recipe). 9 statements passed dalal’s source checks. 2 did not and are not shown.

pick history

every time it was listed, and how it went.

never on a list so far.

in the knowledge base

the latest filings and news.

research ideas and things to consider, not personalised investment advice. every statement links to the filing or article it came from; numbers are computed by dalal from exchange data with their dates. ideas can and do lose money: the track record shows every pick, losers included. decide based on your own situation.